logo-loader
HealthPharma & Biotech
VentriPoint Diagnostics Ltd.

Ventripoint Diagnostics shares pump after positive findings from sarcoidosis study in Netherlands using VMS

Pulmonary hypertension occurs in 6% to 74% of patients with sarcoidosis ...

1546868762_Heart.jpg
Cardiac specialists at the hospital in the Netherlands are using the med-tech group's VMS system

Ventripoint Diagnostics Ltd (CVE:VPT) (OTCMKTS:VPTDF) revealed its VMS heart monitoring system was again proving its worth - after positive results from the St Antonius Hospital in the Netherlands, sending shares in the company higher.

Cardiac specialists there are using the med-tech group's VMS system to study patients with sarcoidosis, an inflammatory disease, which affects multiple organs in the body, including the heart.

READ: Ventripoint says Johns Hopkins doctor cited VMS+ heart analysis system’s clinical feasibility at Milan conference

The cause of Sarcoidosis is unknown and affects about 50,000 people a year in the US. Between 150,000 and 200,000 people have chronic sarcoidosis.

Pulmonary hypertension occurs in 6% to 74% of patients with sarcoidosis. This is a serious complication leading to early death.

Around 500 sarcoidosis patients have been studied at the Dutch hospital so far. The focus is on the early detection of pulmonary hypertension.

The study has found almost 20 patients with confirmed pulmonary hypertension and the cardiac team will continue to monitor the right-ventricular function of these patients, using the Ventripoint solution, to better understand the progress of the disease.

"The right heart is difficult to assess, and in patients with pulmonary disease, this challenge is even more difficult," said Dr Marloes Huitema, MD Cardiology at St. Antonius Hospital.

"Ventripoint provides a solution that allows us to overcome these barriers and might be an alternative to MRI, which is costly, time consuming and not possible for all patients.

"Furthermore, in those patients with pulmonary hypertension, the Ventripoint technology gives us an ability to repeatedly evaluate the right-ventricular dimensions with a rapid, inexpensive, non-invasive procedure to determine therapeutic efficacy."

Ventripoint noted that there were many potential applications for its VMS technology; providing confidence in the volumetric measurements of patients with accuracy comparable to cardiac MRI (magnetic resource imaging) is its strength.

The group's VMS Plus heart monitoring technology measures whole heart function using conventional ultrasound.

The company has developed a suite of applications for all major heart diseases and wants to commercialize the technology to improve heart care.

Shares in Toronto added almost 12% to $0.19.

Contact Giles at [email protected]

Follow him on Twitter @ Gile74

Quick facts: VentriPoint Diagnostics Ltd.

Price: $0.11

Market: TSX-V
Market Cap: $6.8 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Alchemist sees big market in China for medical cannabis sales

Alchemist (CSE: AMS) CEO Paul Mann and Vice President of Business Development, Asia Pacific Johnson Lee joined Steve Darling from Proactive Vancouver to discuss Alchemist looking for opportunities for cannabis in the emerging cannabis market.  Mann and Lee talk about what the industry...

1 day, 21 hours ago

2 min read